* Reminder: Shift in PERA contributions takes effect this month
   
* CU-Boulder names Boswell interim vice chancellor for diversity
   
* Ingber to take helm of College of Engineering and Applied Science
   
* New College of Music program promises opera from ground up
   
* Five Questions for Robert Kuehler
   
* More than 60 faculty members earn tenure
   
* People
   
* Did you know?
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
  CU-BOULDER
  Performing arts veteran takes helm of Macky Auditorium
 
  UCCS
  El Pomar gift leads to new name for Science and Engineering atrium
 
  UC DENVER
  Shuttle between Denver campuses begins service
 
  ANSCHUTZ MEDICAL CAMPUS
  People with rare cancers needed to help scientists leading new program
 
  TECH TRANSFER
  Aurora company licenses unusual approach to treating inflammatory disease
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
Share your thoughts
   
   
   
   
   
  LETTERS TO THE EDITOR
Share your opinions

CONTACT US
Send your thoughts and suggestions for the Newsletter
   
   
   
   
   

News from the CU system - Tech Transfer

Aurora company licenses unusual approach to treating inflammatory disease

Western States Biopharmaceuticals, Inc. (WSBI), a privately held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

Carl K. Edwards, Ph.D., WSBI's chief scientific officer and a discoverer of the TCISM targets, said, "The goal of WSBI's drug discovery and development research programs is to mediate adaptive immunity (one of two arms of the immune system) while leaving the innate immune system intact. This more selective approach has the potential to result in more effective, yet safer therapies than those currently available to patients."

Said David Norris, chairman of the department of dermatology at the University of Colorado Denver Anschutz Medical Campus and a discoverer of the TCISM targets, "Autoimmune diseases comprise over 100 chronic and often disabling illnesses affecting up to 100 million people worldwide. While there are blockbuster therapies that treat these diseases, they work in only a portion of patients and often lack long-term efficacy. Additionally, because they block the patient's entire immune system, these drugs leave the body vulnerable to infections and even malignancies. TCISM-based therapies could potentially provide physicians and patients improved options for the treatment of many inflammatory diseases."

Aurora-based WSBI is currently advancing its lead molecule - WSBI-711, an antibody against two TCISM targets - into midstage pre-clinical testing. WSBI's other promising TCISM antibody and orally active small molecule therapeutic programs also are progressing towards pre-clinical development.

"TCISMs are a powerful new technology in the battle against autoimmune disease that has the potential to revolutionize standard of care," said Paul Tabor of the CU Technology Transfer Office." The university is very pleased to memorialize a partnership with Western States Biopharmaceuticals, a company we believe is ideally positioned to bring this technology forward."

Bookmark - Print - Share

 
Previous Tech Transfer Stories

06/30/2010
Optioned device helps diagnose acid reflux, other esophageal diseases

06/16/2010
Taste Connections licenses CU low-protein meat supplement

05/26/2010
White House turns to CU for input on technology commercialization

05/05/2010
Biotech company expands Alzheimer's disease partnership with CU

04/21/2010
Sanofi Pasteur licenses E. coli vaccine technology

04/07/2010
CU ranked 14th among universities in 'Patent Power'

03/31/2010
CU cardiovascular monitoring technology to be commercialized

03/10/2010
Israel-based company licenses water desalination technology

03/03/2010
Colorado company licenses CU test to assess chronic liver disease

01/20/2010
AgriHouse completes license for CU water management technology

01/13/2010
AmideBio licenses technology from CU

01/06/2009
Business collaboration leads to high ranking for CU-Boulder

12/16/2009
License agreement gives Viral Genetics Inc. right to develop cancer therapies

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app